Review our pipeline for a detailed overview of our key initiatives and their status in the development and testing process.

#MVMD
Moves Faster

MVMD is here to change the world. To push the boundaries of science and exploration. To go beyond possible… and reach for the stars into the universe of all things impossible. 

Our patented technologies are embedded across critical projects that are focused on doing more with less, making world-class drugs and vaccines more accessible, and driving significant inefficiencies and costs out of the legacy manufacturing and distribution systems.   

Review our product pipeline below for a detailed overview of our key initiatives and related status.

Swipe to View Pipeline.

Program

Tech

Market

Value Proposition

Macrocyclic Lactone Solubilization

Patented Quicksome™ liposome technology utilizes an advanced 2-step encapsulation and desiccation process to formulate normally highly un-bioavailable active ingredients into highly effective rapid oral dissolving product formats.

Quicksome™

Patented Quicksol™ technology for macrocyclic lactones, including Ivermectin and Selamectin, to enable enhanced injection or other liquid application of poorly soluble drugs to enhance bioavailability with new delivery options. 

Quicksol™

Drug, Human Therapeutic, Animal Parasitic

Significant improvement over current oral form ivermectin drug –waterless oral dissolve, dramatically quicker onset, zero decline over extended periods in the body, less variability, requires a fraction of the Ivermectin API, uses strictly excipients that are currently approved by the US Food and Drug Administration (FDA), leading candidate for human injection and sublingual applications, broader husbandry and companion animal applications based on low viscosity. Implications for COVID-19 viral clearance, prophylactic, and broader applications for the elimination of malaria and dengue. 

2021
2022
Status
Q1
Q2
Q3
Q4
Q1 - Q4
Formulation lab work on solubilization of Ivermectin
Completed
Patent filing for macrocyclic lactone drugs. Accelerated application examination requested.
Completed
Pre-clinical trials for solubilized rapid dissolve and intramuscular delivery
Completed
API sourcing / supply contracting
Completed
BSL-4 COVID-19 clearance trial
Completed
Sourcing husbandry animal pre-clinical applications
Completed
Conducting husbandry clinical trials: Cattle, Swine, Goat, and Poultry
Completed
GMP production of solubilized ivermectin for rapid dissolve and intramuscular formats
In progress
505(b)(2) pathway with the U.S. Food and Drug Administration (FDA)
In progress
Human clearance trial
Pending
Partnering licenses / ivermectin production evaluation
In Progress

Oncology

Patented Quicksome™ liposome technology utilizes an advanced 2-step encapsulation and desiccation process to formulate normally highly un-bioavailable active ingredients into highly effective rapid oral dissolving product formats.

Quicksome™

Patented Quicksol™ technology for macrocyclic lactones, including Ivermectin and Selamectin, to enable enhanced injection or other liquid application of poorly soluble drugs to enhance bioavailability with new delivery options. 

Quicksol™

Oncology

Ivectosol™ being tested to target certain cancers to pursue novel human intratumoral injection and intravenous infusion.

2021
2022
Status
Q1
Q2
Q3
Q4
Q1 - Q4
Initial Ivermectin Oncology Research
Completed
Patent filing for cancer adjuvant, Novel Injectable, Infusable, Instillable Ivermectin Adjuvant for Cancer Therapies for its solubilized ivermectin (Ivectosol™).
Completed
Preclinical Study One: Triple-negative breast cancer

Study is testing the effectiveness of Ivectosol™ combined with checkpoint inhibitor that would be equivalent to either OPDIVO or Keytruda for disease progression and complete response rate. Arms in the study are looking at single checkpoint inhibitor, oral IVM + checkpoint inhibitor and intratumoral IVM + checkpoint inhibitor.

Triple-negative breast cancer
In Progress
Preclinical Study Two: Metastatic melanoma

Study is testing the effectiveness of Ivectosol™ intratumorally combined with checkpoint inhibitor for disease progression and complete response rate. Arms in the study are looking at single checkpoint inhibitor, oral IVM + check pointinhibitor and intratumoral IVM + checkpoint inhibitor

Metastatic melanoma
In Progress
Preclinical Study Three: Lewis lung carcinoma as a proxy for non-small cell lung carcinoma

Study is testing the effectiveness of Ivectosol™ intratumorally combined with checkpoint inhibitor for disease progression and complete response rate. Arms in the study are looking at single checkpoint inhibitor, oral IVM + checkpoint inhibitor, intratumoral IVM + checkpoint inhibitor, navalbine + intratumoral IVM

Lewis lung carcinoma as a proxy for non-small cell lung carcinoma
In Progress

Dose Sparing Adjuvant

Patented Quicksome™ liposome technology utilizes an advanced 2-step encapsulation and desiccation process to formulate normally highly un-bioavailable active ingredients into highly effective rapid oral dissolving product formats.

Quicksome™

Dose Sparing Adjuvant

Patent-Pending Porous Aluminum Nanostructure Adjuvant has high surface area for vaccine-antigen binding to provide dose sparing advantages with long-term stability in aqueous media, and greater stability in harsh environments.

Adjuvant

Vaccine

Use less vaccine per dose, cost reduction, increase vaccine output, facilitate mucosal and herd immunity, long-term stability in aqueous media, promote greater stability in harsh environments, inform significant dose sparing applications across hundreds of vaccines, key to global disease eradication 

2021
2022
Status
Q1
Q2
Q3
Q4
Q1 - Q4
Formulation Lab Work
Completed
Electron Micrograph Quantification
Completed
Porous Aluminum Nano-Structured Adjuvant Patent filing / Acceleration Review Request
Completed
Tulane Trials – Dose Sparing and Mucosal Immunity 

The study is comparing existing Alhydrogel adjuvant to the Company’s recently invented stable nano-particulate adjuvant by both intramuscular injection and intradermal injection immunization, evaluating the antibody responses following vaccination with fractional doses of IPV comparing delivery types with IPV alone or adjuvanted.

Tulane Trials – Dose Sparing and Mucosal Immunity 
In Progress
Partnering Licenses
In Progress
Human Trials
Pending
Expanded Spectrum Vaccine Dose Sparing Evaluations
Pending

Cold Chain

Patented Quicksome™ liposome technology utilizes an advanced 2-step encapsulation and desiccation process to formulate normally highly un-bioavailable active ingredients into highly effective rapid oral dissolving product formats.

Quicksome™

Dose Sparing Adjuvant

Patent-Pending Porous Aluminum Nanostructure Adjuvant has high surface area for vaccine-antigen binding to provide dose sparing advantages with long-term stability in aqueous media, and greater stability in harsh environments.

Adjuvant

Vaccine

Enable distribution outside of cold chain, use less vaccine per dose, cost reduction, increase vaccine output, key to global disease eradication

2021
2022
Status
Q1
Q2
Q3
Q4
Q1 - Q4
Formulation Lab Work
Completed
FDA confirmation of stabilization and preservation of Polio D Antigen via Quicksome™
Completed
Preliminary cold chain testing: 25°C
Completed
Optimization work, vial embed, rapid dry
Completed
FDA collaborative research agreement
Completed
FDA cold chain testing on novel desiccated vial format
In Progress
Manufacturing Application / Elisa validation
Pending
Quicksome™ sublingual vaccine pre-clinical / clinical trials
Pending

Expanded Ivermectin Applications

Patented Quicksome™ liposome technology utilizes an advanced 2-step encapsulation and desiccation process to formulate normally highly un-bioavailable active ingredients into highly effective rapid oral dissolving product formats.

Quicksome™

Patented Quicksol™ technology for macrocyclic lactones, including Ivermectin and Selamectin, to enable enhanced injection or other liquid application of poorly soluble drugs to enhance bioavailability with new delivery options. 

Quicksol™

Human Parasitic, Therapeutic, Animal Parasitic

Enhanced treatment options and effectiveness across broad ectoparasitic applications.

2021
2022
Status
Q1
Q2
Q3
Q4
Q1 - Q4
Invitro testing for targeted ectoparasites control - lice, ticks, bedbugs
Pending
Pre-clinical to test liquid shampoos, drenches for both animal and human health applications
Pending
Partner licensing
Pending

Selamectin

Patented Quicksome™ liposome technology utilizes an advanced 2-step encapsulation and desiccation process to formulate normally highly un-bioavailable active ingredients into highly effective rapid oral dissolving product formats.

Quicksome™

Patented Quicksol™ technology for macrocyclic lactones, including Ivermectin and Selamectin, to enable enhanced injection or other liquid application of poorly soluble drugs to enhance bioavailability with new delivery options. 

Quicksol™

Human Parasitic, Therapeutic, Animal Parasitic

No current human forms – solubilized pursuit would open up applications similar to MVMD’s work with ivermectin – waterless oral dissolve, inhalable, or injectable, dramatically quicker onset, zero decline over extended periods in the body, less variability, requires a fraction of the API, uses strictly excipients that are currently approved by the US Food and Drug Administration (FDA), leading candidate for human injection and sublingual applications, broader husbandry and companion animal applications based on low viscosity.  Pursuing implications for Tuberculosis treatment.

2021
2022
Status
Q1
Q2
Q3
Q4
Q1 - Q4
Solubilization and formulation work on Selamectin
Completed
Pre-clinical trials for solubilized rapid dissolve and intramuscular delivery
Pending
Animal solubilization pre-clinical
Pending

Sublingual Pharmaceutical

Patented Quicksome™ liposome technology utilizes an advanced 2-step encapsulation and desiccation process to formulate normally highly un-bioavailable active ingredients into highly effective rapid oral dissolving product formats.

Quicksome™

Applications across human pharmaceutical and vaccine space

Stable delivery, waterless oral dissolve, quicker onset, precise dosing, reduced variability, dose sparing, needleless administration, pain elimination, reduced risk of infection and common site injection reactions, reduced complexities for medically supervised administration.

2021
2022
Status
Q1
Q2
Q3
Q4
Q1 - Q4
Formulation work on rapid dissolve oral application with IPV for polio
Completed
FDA confirmation of stabilization and preservation of Polio D Antigen via Quicksome™
Completed
Preliminary cold chain testing: 30°C
Completed
Application of Quicksome™ and cold chain work across BCS Class II drugs, small peptides and proteins
Pending
Partner licensing and molecule identification
Pending

Sublingual Nutraceutical

Patented Quicksome™ liposome technology utilizes an advanced 2-step encapsulation and desiccation process to formulate normally highly un-bioavailable active ingredients into highly effective rapid oral dissolving product formats.

Quicksome™

Applications across human nutraceutical

Stable delivery, waterless oral dissolve, quicker  onset, precise dosing, reduced variability, dose sparing, needleless administration, easy to use formats. 

2021
2022
Status
Q1
Q2
Q3
Q4
Q1 - Q4
Formulation work on rapid dissolve loads across oral powder, chews, wafers and thin strips
Completed
Applications samples developed across Weight loss, Energy, Pre-workout, Recovery, Sleep, Focus, Libido, Smokeless Nicotine and a variety of natural mushroom molecules.
Completed
Ongoing Quicksome™ partner licensing contracting
In Progress

Insulin

Patented Quicksome™ liposome technology utilizes an advanced 2-step encapsulation and desiccation process to formulate normally highly un-bioavailable active ingredients into highly effective rapid oral dissolving product formats.

Quicksome™

Human insulin drug

Stable sublingual delivery, waterless oral dissolve, rapid onset, precise dosing, reduced variability, needleless administration, easy to use format.

2021
2022
Status
Q1
Q2
Q3
Q4
Q1 - Q4
Initial stability and formulation work on rapid dissolve oral application of Humilin R & Humalog
Completed
Pre-clinical trial on efficacy of Humiln R & Humalog molecule
Completed
Enhanced molecule formulation work
In Progress
Pre-clinical trial
Pending

Sublingual Cannabis

Patented Quicksome™ liposome technology utilizes an advanced 2-step encapsulation and desiccation process to formulate normally highly un-bioavailable active ingredients into highly effective rapid oral dissolving product formats.

Quicksome™

Applications across cannabis

Stable delivery, waterless oral dissolve, quicker onset, precise dosing, reduced variability, dose sparing.

2021
2022
Status
Q1
Q2
Q3
Q4
Q1 - Q4
Formulation work on rapid dissolve oral application with THC, CBD
Completed
Quicksome™ partner licensing contracting
Completed

Subscribe to Updates from MVMD

Stay plugged in on everything MVMD.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
*By Clicking "Sign Up" You agree to Mountain Valley MD's Privacy Policy